Sclerochorioretinal abnormalities in hypercholesterolemic rabbits treated with rosiglitazone

Ophthalmic Surgery Lasers and Imaging

Volumn 41, Issue 5, 2010, Pages 562-571

  De Almeida Torres, Rogil José ^a   Muccioli, Cristina ^b   Maia, Maurício ^b,c   Noronha, Lucia ^d   Luchini, Andréa ^e   Alessi, Alexandre ^d   Olandoski, Márcia ^d   Farah, Michel Eid ^b   Précoma, Dalton Bertolin ^d  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital de Olhos Oeste Paulista   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^e Centro Oftalmológico Curitiba   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA DISEASE; SCLERA; SCLERA DISEASE; SENESCENCE;

ADMINISTRATION, ORAL; ANIMALS; CHOLESTEROL, DIETARY; CHOROID DISEASES; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; MALE; RABBITS; RETINAL DISEASES; SCLERAL DISEASES; THIAZOLIDINEDIONES;

EID: 77957962301     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20100726-05     Document Type: Article

References (47)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis APA. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
2. Tan JSL, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration. Ophthalmology. 2007;114:1143-1150.
3. Miceli MV, Newsome DA, Tate DJ Jr, Sarphie TG. Pathologic changes in the retinal epithelium and Bruch's membrane of fat-fed atherogenic mice. Curr Eye Res. 2000;20:8-16.
4. Ong JM, Zorapapel NC, Rich KA, et al. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest Ophthalmol Vis Sci. 2001;42:1891-1900.
5. Triviño A, Ramírez AI, Salazar JJ, et al. A cholesterol-enriched diet induces ultrastructural changes in retinal and macroglial rabbit cells. Exp Eye Res. 2006;83:357-366.
6. Ramírez AI, Salazar JJ, De Hoz R, et al. Macroglial and retinal changes in hypercholesterolemic rabbits after normalization of cholesterol levels. Exp Eye Res. 2006;83:1423-1438.
7. Salazar JJ, Ramírez AI, de Hoz R, et al. Alterations in the choroid in hypercholesterolemic rabbits: reversibility after normalization of cholesterol levels. Exp Eye Res. 2007;84:412-422.
8. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37:3483-3493.
9. Hu J, Van Eldik LJ. S100 beta induces apoptotic cell death in cultured astrocytes via a nitric oxide-dependent pathway. Biochim Biophys Acta. 1996;1313:239-245.
10. Yücel I, Akar Y, Yücel G, Çiftçioglu MA, Keles N, Aslan M. Effect of hypercholesterolemia on inducible nitric oxide synthase expression in a rat model of elevated intraocular pressure. Vision Res. 2005;45:1107-1114.
11. Dashti N, McGwin G, Owsley C, Curcio CA. Plasma apolipoproteins and risk for age related maculopathy. Br J Ophthalmol. 2006;90:1028-1033.
12. McGwin G, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology. 2005;112:488-494.
13. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:2309-2317.
14. Pershadsingh HA. Peroxisome proliferator-activated receptor gamma: therapeutic target for disease beyond diabetes: quo vadis? Expert Opin Investig Drugs. 2004;13:215-228.
15. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
16. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Atheroscler Thromb Vasc Biol. 1999;19:2094-2104.
17. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
18. Han KH, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor. J Clin Invest. 2000;106:793-802.
19. Patel CB, De Lemos JA, Wyne KL, McGuire DK. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR gamma agonism. Diab Vasc Dis Res. 2006;3:65-71.
20. Kurebayashi S, Xu X, Ishii S, Shiraishi M, Kouhara H, Kasayama S. A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. Atherosclerosis. 2005;182:71-77.
21. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126.
22. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578-3585. (Pubitemid 36909798)
23. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinases inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:2194-2200.
24. Lambert V, Munaut C, Noël A, et al. Influence of plasminogen activator inhibitor type I on choroidal neovascularization. FASEB J. 2001;15:1021-1027. (Pubitemid 32290790)
25. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:2743-2749.
26. Sun YP, Lu NC, Parmley YWW, Hollenbeck CB. Effects of cholesterol diets on vascular function and atherogenesis in rabbits. Proc Soc Exp Biol Med. 2000;224:166-171.
27. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptorgamma agonist in hypercholesterolemia. Circulation. 2003;108:2805-2811.
28. Liu HR, Tao L, Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004,62:135-144.
29. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PGH, de Jong PTVM. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857-2864.
30. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130:658-663.
31. Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 1997;124:677-682.
32. Broekhuyse RM. The lipid composition of aging sclera and cornea. Ophthalmologica. 1975;171:82-85.
33. Friedman E, Krupsky S, Lane AM, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995;102:640-646.
34. Friedman E, Ivry M, Ebert E, Glynn R, Gragoudas E, Seddon J. Increased scleral rigidity and age-related macular degeneration. Ophthalmology. 1989;96:104-108.
35. Torres RJA, Maia M, Noronha L, et al. Evaluation of choroid and sclera early alterations in hypercholesterolemic rabbits: histologic and histomorphometric study [article in Portuguese]. Arq Bras Oftalmol. 2009;72:68-74.
36. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411-2417.
37. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
38. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104.
39. Torres RJA, Maia M, Muccioli C, et al. Evaluation of early chorioretinal abnormalities in hypercholesterolemic rabbits submitted to the peroxisome proliferator-activated (PPAR)-gamma agonist treatment (rosiglitazone): histological and histomorphometric study. Vision Pan- America. 2009;8:152-154.
40. Biling-Marczak K, Kuznicki J. Calretinin: sensor or buffer-function still unclear. Pol J Pharmacol. 1999;51:173-178.
41. Ramirez JM, Triviño A, Ramirez AI, Salazar JJ, García- Sanches J. Structural specializations of human retinal glial cells. Vision Res. 1996;36:2029-2036.
42. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256.
43. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
44. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Ver Med. 2003;54:321-341.
45. Völgyi B, Pollák E, Buzás P, Gabriel R. Calretinin in neurochemically well-defined cell populations of rabbit retina. Brain Res. 1997;763:79-86.
46. Cogan DG, Kuwabara T. Ocular changes in the experimental hypercholesterolemia. Arch Ophthalmol. 1959;61:219-225.
47. Seki N, Bujo H, Jiang M, et al. A potent activator of PPAR alpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis. 2005;178:1-7.